A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

  • STATUS
    Recruiting
  • End date
    May 15, 2023
  • participants needed
    80
  • sponsor
    Daiichi Sankyo, Inc.
Updated on 13 February 2021
Investigator
Daiichi Sankyo Contact for Clinical Trial Information
Primary Contact
The Cancer Institute Hospital of JFCR (6.7 mi away) Contact
+42 other location
platelet count
measurable disease
anticoagulants
vegf
growth factor
international normalized ratio
metastasis
oxaliplatin
neutrophil count
fluoropyrimidine
liver metastasis
irinotecan
bevacizumab
aptt
thromboplastin
solid tumour
vascular endothelial growth factor
microsatellite instability high

Summary

This study is designed to primarily evaluate the safety and efficacy of U3-1402 in participants with advanced or metastatic colorectal cancer (CRC) who have received at least 2 prior lines of therapy and will explore clinical benefit according to human epidermal growth factor receptor 3 (HER3) tumor expression level in otherwise refractory tumors.

Description

There will be 2 cohorts with enrollment in 2 parts. Participants will be treated on Day 1 of each 21-day cycle (every 3 weeks) with U3-1402 5.6 mg/kg intravenous (IV). The estimated treatment period is approximately 8 months and the follow-up period is approximately 4 months.

Details
Condition Metastatic Colorectal Cancer
Treatment U3-1402
Clinical Study IdentifierNCT04479436
SponsorDaiichi Sankyo, Inc.
Last Modified on13 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Participant has provided written informed consent prior to the start of any study specific procedures
Participants 18 years (follow local regulatory requirements if the legal age of consent for study participation is >18 years old)
Pathological/histological confirmation of advanced or metastatic colon or rectal adenocarcinoma
Must be resistant, refractory, or intolerant to at least 2 prior lines of systemic therapy, that must include all of the following agents
Fluoropyrimidine
Irinotecan
Platinum agents (e.g, oxaliplatin)
An anti-epidermal growth factor receptor (EGFR) agent, if clinically indicated
An anti-VEGF agent, if clinically indicated (eg, bevacizumab)
An immune checkpoint inhibitor (eg, microsatellite instability-high [MSI-H] status)
Has at least 1 measurable lesion confirmed by blinded independent central review (BICR) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1
A BRAF inhibitor, if clinically indicated (eg, BRAF V600E positive)
Pre-treatment tumor biopsy. Participants may be exempted from the requirement to provide a pre-treatment tumor biopsy if archival tumor tissue was collected within 3 months of screening during or after treatment with the last prior cancer treatment and is of sufficient quantity (2 cores or 20 slides with adequate tumor tissue content)
Willing to provide a required pre-treatment tumor biopsy and an additional archival tissue sample for the assessment of HER3 expression levels by immunohistochemistry and exploratory biomarkers, defined as
Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
An additional archival tissue sample collected greater than 3 months prior to screening must be available and of sufficient quantity, as defined above, at the time of screening. If an archival tissue sample (collected greater than 3 months prior to screening) is not available, a subject may be included provided the pre-treatment tumor biopsy is obtained and after discussion and agreement from Sponsor (Medical Monitor or designee)
Life expectancy 3 months
Consent to provide on-treatment tumor biopsy. When at least 10 treatment tumor biopsies have been collected, the Sponsor will provide written notification of a change to the requirement
Has adequate bone marrow reserve and organ function at baseline based on local laboratory data defined as follows within 14 days prior to Cycle 1 Day 1
Platelet count: 100,000/mm^3 or 100 10^9/L (platelet transfusions are not allowed up to 14 days prior to Cycle 1 Day 1 to meet eligibility)
Hemoglobin: 9.0 g/dL (transfusion and/or growth factor support is allowed)
Absolute neutrophil count: 1500/mm^3 or 1.5 10^9/L
Serum creatinine (SCr) OR creatinine clearance (CrCl): SCr 1.5 upper limit of normal (ULN), OR CrCl 30 mL/min as calculated using the Cockcroft- Gault equation or measured CrCl; confirmation of CrCl is only required when creatinine is >1.5 ULN
Alanine aminotransferase /aspartate aminotransferase: 3 ULN (if liver metastases are present, 5 ULN)
Total bilirubin: 1.5 ULN if no liver metastases (<3 ULN in the presence of documented Gilbert's syndrome [unconjugated hyperbilirubinemia] or liver metastases)
Prothrombin time (PT) or PT-international normalized ratio (INR) and activated partial thromboplastin time (aPTT) / partial thromboplastin time (PTT): 1.5 ULN except for subjects on coumarin- derivative anticoagulants or other similar anticoagulant therapy, who must have PT-INR within therapeutic range as deemed appropriate by the Investigator
Serum albumin: 2.5 g/dL

Exclusion Criteria

any autoimmune, connective tissue or inflammatory disorder with pulmonary involvement (eg, rheumatoid arthritis, Sjgren's syndrome, sarcoidosis)
OR prior complete pneumonectomy
Is receiving chronic systemic corticosteroids dosed at >10 mg prednisone or equivalent anti-inflammatory activity or any form of immunosuppressive therapy prior to Cycle 1 Day 1. Participants who require use of bronchodilators, inhaled or topical steroids, or local steroid injections may be included in the study
Evidence of clinically active spinal cord compression or brain metastases
Any history of interstitial lung disease (including pulmonary fibrosis or radiation pneumonitis), has current interstitial lung disease (ILD), or is suspected to have such disease by imaging during screening
Monoclonal antibodies other than immune checkpoint inhibitors, such as bevacizumab (anti-VEGF) and cetuximab (anti-EGFRs) <28 days
Clinically severe pulmonary compromise (based on Investigator's assessment) resulting from intercurrent pulmonary illnesses including, but not limited to
any underlying pulmonary disorder (e.g., pulmonary emboli, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion)
Evidence of leptomeningeal disease
Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 Grade 1 or baseline
Inadequate washout period prior to Cycle 1 Day 1 of U3-1402
Whole brain radiation therapy <14 days or stereotactic brain radiation therapy <7 days
Any cytotoxic chemotherapy, investigational agent or other anticancer drug(s) from a previous cancer treatment regimen or clinical study <14 days or 5 half-lives, whichever is longer
Known Hepatitis B and/or Hepatitis C infection, such as those with serologic evidence of viral infection within 28 days of Cycle 1 Day 1
Immune checkpoint inhibitor therapy <21 days
Participants with past or resolved hepatitis B virus (HBV) infection are eligible
Major surgery (excluding placement of vascular access) <4 weeks
if
Radiotherapy treatment to >30% of the bone marrow or with a wide field of radiation <28 days or palliative radiation therapy <14 days
Hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (anti-HBc) positive; OR
Chloroquine/hydroxychloroquine 14 days
HBsAg positive and HBV deoxyribonucleic acid (DNA) viral load is documented to be 2000 IU/mL in the absence of anti-viral therapy and during the previous 12 weeks prior to the viral load evaluation with normal transaminases values (in the absence of liver metastasis); OR
Prior treatment with an anti-HER3 antibody and/or antibody drug conjugate (ADC) that consists of an exatecan derivative that is any topoisomerase I inhibitor (e.g, trastuzumab deruxtecan)
HBsAg positive and HBV DNA viral load is documented to be 2000 IU/mL in the absence of anti-viral therapy and during the previous 12 weeks prior to the viral load evaluation for participants with liver metastasis and abnormal transaminases with a result of AST/ALT <3 ULN. 2. Participants with a history of hepatitis C infection will be eligible for enrollment only if the viral load according to local standards of detection is documented to be below the level of detection in the absence of anti-viral therapy during the previous 12 weeks (ie, sustained viral response according to the local product label but no less than 12 weeks, whichever is longer)
Had primary malignancies other than CRC within 3 years prior to Cycle 1 Day 1, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated
Participant with any human immunodeficiency virus (HIV) infection
Any evidence of severe or uncontrolled systemic diseases (including active bleeding diatheses, active infection), psychiatric illness/social situations, geographical factors, substance abuse, or other factors which in the Investigator's opinion makes it undesirable for the participant to participate in the study or which would jeopardize compliance with the protocol. Screening for chronic conditions is not required
Uncontrolled or significant cardiovascular disease prior to Cycle 1 Day 1
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note